Financial Management Professionals Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 7.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,651 shares of the company’s stock after acquiring an additional 117 shares during the quarter. Financial Management Professionals Inc.’s holdings in Johnson & Johnson were worth $293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after buying an additional 777,837 shares during the last quarter. State Street Corp boosted its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after buying an additional 265,330 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after buying an additional 509,818 shares during the last quarter. 68.59% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 1.0 %
Shares of JNJ opened at $163.28 on Thursday. The business’s 50-day moving average price is $168.25 and its 200-day moving average price is $174.16. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock has a market cap of $429.29 billion, a PE ratio of 23.77, a P/E/G ratio of 2.97 and a beta of 0.61. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.77%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.
Johnson & Johnson declared that its board has authorized a stock buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on JNJ shares. UBS Group cut their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley lowered their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Monday, September 12th. SVB Leerink lowered their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Finally, Citigroup lowered their price objective on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $189.78.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.